Barry Samuels, MD

Articles

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphomas

Andreas H. Sarris, MD, PhD;Alexandria T. Phan, MD;A. Goy, MD;Jorge Romaguera, MD;Fredrick B. Hagemeister, MD;Maria A. Rodriguez, MD;Peter Mclaughlin, MD;Barbara Pro, MD;L. Jeffrey Medeiros, MD;Barry Samuels, MD;Ofie Mesina, RN;A. W. Bleyer, MD;Fernando Cabanillas, MD

August 1st 2002

Because irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or refractory non-Hodgkin’s lymphomas (NHLs). Irinotecan at 300 mg/m² IV was administered every 21 days with intensive loperamide management of diarrhea.

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphoma

Andreas H. Sarris, MD, PhD;Jorge Romaguera, MD;Fredrick B. Hagemeister, MD;Maria A. Rodriguez, MD;Peter Mclaughlin, MD;Barbara Pro, MD;Anas Younes, MD;Ofie Mesina, RN;Fernando Cabanillas, MD;L. Jeffrey Medeiros, MD;Barry Samuels, MD

July 1st 2001

Irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity. Various schedules and doses have been studied, and major complications were delayed diarrhea and